Inflamm Bowel Dis. 2024 May 2;30(5):829-843. doi: 10.1093/ibd/izad120.

Shubha Bhat ^1 2, Benjamin Click ³, Miguel Regueiro ¹

Author information

¹Department of Gastroenterology, Hepatology, and Nutrition, Cleveland Clinic Foundation, Cleveland, Ohio, USA.

²Department of Pharmacy, Cleveland Clinic Foundation, Cleveland, Ohio, USA.

³Division of Gastroenterology and Hepatology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.

Abstract

The recent approval of new medications with novel mechanisms of action and emergence of updated safety information for existing therapies has changed the treatment landscape of inflammatory bowel disease (IBD). These advances led to unique adverse effect profiles and identification of new safety signals, resulting in the evolution of the safety, monitoring, and positioning of IBD therapies. In this updated review, we (1) examine the existing and updated safety data of monoclonal antibodies and small molecules for IBD, with a focus on recently Food and Drug Administration (FDA)-approved therapies, and (2) propose risk stratification and assessment considerations prior to and during IBD treatment.